1. Abigerges D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210–221.
2. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896–903.
3. André T, Bensmaine MA, Louvet C, Lucas V, Beerblock K, Desseigne F, Francois E, Merrouche A, Bouché O, Morvan F, Carola E, de Gramont A (1997) Addition of oxa-liplatin (Elaoxtine®) to the same leucovorin and 5-fluorouracil bimonthly regimens after pregression in patients with metastatic colorectal cancer: Preliminary report. Proc Am Soc Clin Oncol 16: abs 958.
4. Anton A, Aranda E, Carrato A, Artal A, Marcuello E, Massud B, Cervantes A, Abad A, Satre J, Fernández-Martos C, Gallén M, Huarte L, Balcells M, Miguel Servet H (1998) Phase II study of irinotecan (CPT-11) in the treatment of patients with advanced colorectal cancer (ACRC) resistant to 5-fluorouracil (5-FU) based chemotherapy. The experience of TTD Spanish cooperative group. Proc Am Soc Clin Oncol 17: abs 1071.
5. Becouarn Y, Ychou M, Ducreux M, Borei C, Betheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Palliot B, Raoul JL, Duffour Y, Faudi A, Dupont-Anre G, Rougier P (1998) Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16: 2739–2744.